Simcere Diagnostics

Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical Group’s subsidiary Simcere Diagnostics, has been approved by the National Medical Products Administration (NMPA) as a Category III product. The kit is designed for the qualitative detection of CYP2C19 gene polymorphism in peripheral blood samples…